Cover Image of Herunterladen Lipid Manager  APK

4.9/5 - 12 Stimmen

ID: org.acc.ldlmanager

APK jetzt herunterladen

Die Beschreibung von Lipid Manager


The ACC Lipid Manager app (formerly LDL-C Manager) provides 4-tools-in-1 to help clinicians manage a patient’s triglycerides and LDL-C from therapy initiation through treatment calibration with the goal of lowering ASCVD risk:
-ASCVD Risk Estimator: Calculate pretreatment ASCVD risk and determine the appropriateness of statin therapy for the patient
-LDL-C Lowering Therapy tool: Assess response to a statin, and determine if other therapies should be considered and in what order
-Statin Intolerance tool: Evaluate the patient for possible statin intolerance, and determine appropriate next steps
-Hypertriglyceridemia tool: Use the app to see tailored consensus recommendations for both lifestyle intervention and pharmacological management of high-risk patients with persistent hypertriglyceridemia
The information and recommendations in this App are not meant to represent the only or best course of care nor replace clinical judgement. Therapeutic options should be determined after discussion between the patient and their care provider.
— Statin Intolerance tool: Evaluate the patient for possible statin intolerance, and determine appropriate next steps
The information and recommendations in this App are not meant to represent the only or best course of care, or replace clinical judgment. Therapeutic options should be determined after discussion between the patient and their care provider.
Zeig mehr
  • Kategorie

    Medizinisch
  • Mach es an:

    Go Google Play org.acc.ldlmanager
  • Anforderungen:

    Android Varies with device+

Lipid Manager Varies with device APK zum Android Varies with device+

Ausführung Varies with device zum Android Varies with device+
Aktualisieren am 2023-02-05
Installiert 10.000++
Dateigröße 34.035.389 bytes
Berechtigungen Berechtigungen anzeigen
Was gibt's Neues This app has been updated in accordance with the 2022 ACC ECDP on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk to incorporate newer nonstatin agents, such as bempedoic acid, evinacumab, and inclisiran. This update also includes improved risk discrimination in patient evaluation, now incorporating CAC scoring, evidence of subclinical atherosclerosis, and Familial Hypercholesterolemia.

Versionsgeschichte:

Zeig mehr
Hit APK
Zeig mehr